Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02886585 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab In Central Nervous System Metastases
A Phase 2 study of Brain Metastases, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
- 2
- Study locations
NCT02886585 is a Phase 2 study of Brain Metastases that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 101 participants, below the 211-participant average among 67 other Brain Metastases trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02886585, a Phase 2 study of Brain Metastases, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- PROCEDURE Stereotactic Radiosurgery
- RADIATION MRI
- RADIATION PET/CT
Study Locations (2)
Massachusetts
- Priscilla Brastianos - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2016-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02886585
The ClinicalTrials.gov registry entry for NCT02886585 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 67 other Brain Metastases trials with a reported enrollment target (52% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02886585 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02886585 about?
NCT02886585 is a clinical study titled "Pembrolizumab In Central Nervous System Metastases". This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
What is the current status of trial NCT02886585?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2016-10. Estimated completion is 2027-12.
What conditions does trial NCT02886585 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT02886585?
The interventions under investigation include: Pembrolizumab (DRUG), Stereotactic Radiosurgery (PROCEDURE), MRI (RADIATION), PET/CT (RADIATION).
Who is sponsoring clinical trial NCT02886585?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02886585 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.